Granzyme B Imaging Agents for Immune Response Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging technologies face challenges in effectively assessing cancer immunotherapy efficacy and monitoring immune responses, as they often rely on overall survival endpoints and struggle to differentiate between tumor growth and immune cell infiltration, making it difficult to determine individual patient responses to cancer treatments.
Innovation Solution
Development of heterocyclic compounds that act as Granzyme B imaging agents, specifically binding to Granzyme B and incorporating imaging agents like radioisotopes (e.g., 18F) for positron emission tomography (PET) imaging, allowing for precise visualization of immune responses and treatment monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging technologies are used to assess cancer immunotherapy efficacy, then overall survival endpoints are employed, but the ability to differentiate between tumor growth and immune cell infiltration is poor
Solution Approach 1:
The patent employs PET imaging technology to detect Granzyme B-specific radioactivity distribution in the body, creating a visual 'color map' that distinguishes immune cell infiltration (high Granzyme B signal) from tumor growth (low or absent signal). This functional imaging approach transforms invisible immune responses into detectable radiotracer signals, enabling precise differentiation between treatment responses that conventional imaging cannot distinguish.
2Measurement precision
If Granzyme B-specific imaging agents are developed, then precise visualization of immune responses is achieved, but the complexity of the imaging system increases
Solution Approach 1:
The patent introduces Granzyme B-specific small molecule inhibitors conjugated with PET radiotracers as intermediary agents. These molecules specifically bind to Granzyme B enzyme active sites, serving as mediators that translate invisible immune cell activity into detectable radiotracer signals. This targeted molecular probe approach enables precise immune response visualization without requiring complex imaging equipment beyond standard PET scanners.
3Adaptability or versatility
If conventional imaging methods are used, then existing technology is maintained, but the ability to monitor individual patient responses to cancer treatments is insufficient
Solution Approach 1:
The patent enables localized functional imaging by detecting Granzyme B-specific radioactivity distribution at specific tumor sites and immune cell infiltration regions. This allows personalized assessment of immune response heterogeneity within individual patients, identifying which specific tumors or tissue regions are responding to immunotherapy. The method provides patient-specific functional information that can guide personalized treatment decisions rather than relying on population-level overall survival data.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate imaging of Granzyme B in subjects, providing a novel biomarker for assessing cancer immunotherapy efficacy and monitoring immune responses, potentially improving treatment outcomes by offering a more precise method to evaluate treatment effectiveness.
Implementation Method 1
Granzyme B is a serine-protease released through exocytosis by cytotoxic lymphocytes (CTL) during the cellular immune response
Implementation Method 2
incorporating imaging agents like radioisotopes (e.g., 18F) for positron emission tomography (PET) imaging
Data Source
AI summary
Provided herein are heterocyclic compounds useful for imaging Granzyme B. Methods of imaging Granzyme B, combination therapies, and kits comprising the Granzyme B imaging agents are also provided.